Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 94, Issue 6, Pages 697-709Publisher
WILEY
DOI: 10.1002/ajh.25475
Keywords
-
Categories
Funding
- Janssen Pharmaceuticals
- Asahi Kasei Pharma Corporation
- Diagnostica Stago
- Servier Canada
- CSL Behring
- BMS Canada
- Octapharma
- Shionogi
- Leo Pharma Research Foundation
- Heart and Stroke Foundation
- Syntimmune
- Spark Therapeutics
- Shire
- Pfizer
- Novo Nordisk
- Bioverativ
- Bayer
- Alexion
Ask authors/readers for more resources
Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban and rivaroxaban reversal. Non-specific prohemostatic agents such as prothrombin complex concentrate (PCC) and activated PCC have also been used for DOAC reversal. The goal of this document is to provide comprehensive guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding use of DOAC reversal agents. We discuss indications for reversal, provide guidance on how the individual reversal agents should be administered, and offer suggestions for stewardship at the health system level.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available